Equity research analysts covering Sellas Life Sciences Group (NASDAQ: SLS) have established average 12-month consensus price targets centered around $10.00 per share. These forecasting models factor in ongoing clinical trials for its principal immunotherapy candidates, regulatory developments, and potential future commercialization milestones. Because clinical-stage pharmaceutical valuations depend heavily on trial readouts, individual price targets are subject to routine updates by covering financial institutions.